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Nephrotic syndrome is one of risk factors that contribute to the 
development of hyperlipidemia, which is a leading cause of coronary heart 
disease of coronary heart disease in adult life. 
The objectives of this study were to determine lipid profile of children with 
nephrotic syndrome and to study the correlation of hyperlipidemia and 
some of risk factors. 
A cross-sectional prospective hospital based study was carried out during 
the period from March 2006 to August 2006.  The study was conducted at 
Dr. Salma Dialysis and Renal Transplant Centre, Omdurman Teaching 
Hospital, Gaafar Ibn Auf Children Emergency Hospital and Soba Hospital. 
Sixty children, who fulfilled the criteria of nephrotic syndrome, were 
enrolled in this study.  First consent was taken history, physical examination 
and required investigation were done including; serum lipid (cholesterol, 
LDL, TG), serum albumin and serum creatinine. 
The age of the patients ranged between 2-15 years with peak age of 2-5 years 
(43.3%) and the mean of 8.4 + 4.06 years.  There was obvious male 
predominance, where male constituted (63.3%) of the study group and 
female were (36.7%), giving a ratio of 1.9 : 1. 
Hyper cholesterolemia was found in (66.7%) of study group, hyperlipidemia 
of LDL (63.3%) and hypertriglyceridemia were found in (63.3%) while low 
HDL was found in (26.7%). 
All patients in relapse and those resistant to steroid therapy, and most of 
those on remission had elevated cholesterol (59.2%), LDL (55.1%) and 
triglyceride (63.2%). 
Positive correlation was found between dyslipidemia and duration of 
nephrotic syndrome, blood pressure and renal impairment and negative 
correlation with serum albumin. 
Conclusions: lipid abnormalities are common finding in patient with 
nephrotic syndrome.    
Relapse, resistant to steroid, high blood pressure, prolonged duration and 
renal impairment are high risk factor to hyperlipidemia. 
Recommendation:  lipid profile is recommended in nephrotic children. 
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Chapter One 
1-  Introduction and Literature Review 
 
1.1 Introduction:   
1.1.1 Definition 
 Nephritic syndrome is a clinical entity characterized by massive loss of 
urinary protein (albuminuria > 1 g/m2/24 hrs) leading to hypoproteinemia 
(serum albumin < 2.5 g/dl) and its result in edema.  Hyperlipidemia, 
hypercholesterolemia and increased lipiduria are usually associated(1).  
 
1.1.2 Historical Background: 
 The term nephrosis or nephrotic syndrome, had its origin in the early 
20th century and was introduced primarily to distinguish it from nephritis.  It 
described a clinical state of edema and proteinuria in which the renal 
histology (in light microscopy) demonstrate fatty degeneration of tubule 
associate with normal appearing glumeruli.  Briefly the name was modified 
to the lipoid nephrosis after the routine finding of lipid droplets in the urine of 
affected patients. 
 There is variation in the epidemiology, aetiology prognosis and the 
natural history between temperate and tropical regions and even within the 
same country and among different races living in the same country(2). 
 
1.1.3      Epidemiology: 
1.1.3.1      The primary nephrotic syndrome 
Prevalence of NS is 2-5 cases per 105 children leading to accumulative 
prevalence of 15.7 per 105 children(3). 
The International Study of Kidney Disease in Children (ISKDC) 
report that 78.1% of 471 children with primary NS respond to cortico steroid 
therapy and of these 91.8 had minimal change histology(4). 
The peak incidence of both Minimal Changes Nephrotic Syndrome 
(MCNS) and focal segmented NS is in pre-school children (80% is less than 6 
yrs old at presentation).   The median age at diagnosis is 2.5 years for MCNS 
and 6 yrs for FSGS.    In young children boys are more affected than female 
ratio (3:2), but in teenagers and adults the sex ratio is approximately equal.   
The condition is encountered below the age of one year and is certainly rare 
under 6 month of year(6). 
When disease onset occur in child younger than 5 years, the 
likelihood that the lesion is MCNS is greater than 90%, while the risk of focal 
segmented glumerulo sclerosis (FSGS) is 7% and 1% respectively.  
Conversely when disease onset occurs when individual is older than 10 years 
the risk of MCNS drops to approximately 50% and the risk of MPGN 
approach 30%.  FSGS may occur at any age, however, its incidence tend to 
increase slightly with advancing age(7). 
There is variation in the overall prevalence of NS in children and in 
the relative frequency of the different histologic categories in the different 
population.   In the United Kingdom there is higher prevalence of MCNS in 
children from families from the Indian subcontinent than indigenous 
Caucasian population (8). 
In South Africa there is marked racial difference in the histologic 
diagnosis in nephrotic children; black children commonly have membranous 
nephropathy related to hepatitis B infection, whereas white children and 
those of Asian origin predominantly have MCNS(9).   These data reflect the 
importance of both genetic predisposition and environmental factor in 
determining the racial distribution of disease. 
Steroid sensitive nephrotic syndrome occasionally occurs in families.  
In a large European survey, 63 of 1877 (3.4%) nephrotic  children (excluding 
children with congenital nephritic syndrome) had affected siblings of whom 
about half of those presenting more than one year of age were steroid 
responsive with minimal change histology: familial NS breads tree both in 
respect of histopathology and steroid response(10). 
Hardwicke et al(11) reported seasonal proteinuria with pollen 
sensitivity in a patient who had normal glumeruli on renal biopsy since then, 
several investigator have shown that atopy occur in 34-60% of children with 
steroid sensitive NS (10-11) (12). 
1.1.3.2 Congenital nephrotic syndrome: 
 Congenital NS can be subdivided into Finnish type NS (CNS) and 
other types. 
 CNS is specific entity with a known inheritance pattern; others are 
probably a hetrogenous group of disorder such as syphilis and renal vein 
thrombosis.  Another type, diffuse mesangial sclerosis of infancy is rare. 
 Congenital nephrotic syndrome Finnish type (CNF) is most frequent in 
Finland, with initial studies suggesting an incidence of 1.2 per 100,000 birth 
(13).   
 The outcome is invariably poor, only % of these infants reach age one 
year, and only 3% survive until the age of 2 year. the cause of death is usually 
secondary infection. 
 
1.1.4      Aetiology: 
1.1.4.1     Primary Nephrotic Syndrome: 
No definite cause for MCD has been identified. 
Allergies may also be partly responsible since eczema and asthma are 
highly prevalent in patients with MCD. 
1.1.4.2  Secondary NS: 
The term secondary NS related to the clinical state associated with 
others, more clearly defined diseases such as anaphylactoid purpura, systemic 
lupus erythromatosus, diabetes mellitus, sickle cell disease, syphilis and 
update(14), and hodgkin’s disease.  
1.1.4.3  Congenital and infantile nephrotic syndrome: 
These are considered to be and extremely rare inherited nephrosis(15). 
 
1.1.5     Pathogenesis of Nephrotic Syndrome: 
1.1.5.1    Primary nephrotic syndrome: 
The defuse effacement of the foot processes characteristic of minimal 
change disease is viewed only by electron microscopy, and it is partly due to 
abnormal interaction between extra cellular matrix protein and podocytes(16).   
1.1.5.2   Congenital nephrotic syndrome: 
The gene defect responsible for autosomal recessive form is localize to 
the longarm of chromosome 19 and represents a basic defect in the molecular 
structure of the basement membrane, the most striking histological feature is 
marked cystic dilatation of the tubule (mostly proximal and cortical with 
interstitial change (17). 
 
1.1.6     Pathophysiology of Nephrotic Syndrome: 
1.1.6.1   Mechanism of proteinuria: 
In normal individual very little protein is filtered because of the charge 
and the size selectivitiy of the glumerular capillary wall(18). 
Heavy proteinuria is the hall mark of this condition and the primary 
abnormality in NS.  The degree of proteinuria varies considerably from one 
child to another – some children will excrete as much as 15 g/m2/24 hrs, and 
the minimal excretion compatible wit     h the diagnosis is around  1 g/m2/24 
hrs (approximetaly 40 mg/m2/ hrs). 
Initiating event that produces proteinuria remains unknown.  
In primary NS, the glomerular capillary permeability to albumin is 
selectively increased, and this increase in filtered load overcome the modest 
ability of the tubule to reabsorb protein.  This selective proteinuria (as seen in 
minimal change NS) is quite different than the more unselective proteinuria 
observed in cases of glumerulonephritis. Part of this increased protein 
excretion may be because of the smaller size of albumin molecule, but since 
the excretion of some even smaller weight plasma protein is not 
proportionally increased, the present of other factors is obvious. At least 2 
hypothesis are proposed to account for this increased permeability. The 
traditional hypothesis relates to changes in anionic composition of 
glomerular basement membrane(19). 
1.1.6.2  Mechanism of hypoalbuminemia: 
The mechanism of hypoalbuminemia in NS is unresolved. It’s thought 
that most of the decrease serum albumin concentration occurs a consequence 
of the proteinuria(20).   
1.1.6.3   Mechanism of generalize oedema: 
 Oedema is one of major clinical manifestations of nephrotic syndrome.  
Two major mechanisms are thought to cause oedema formation (21-22).  Most 
likely both contribute to the oedema in individual with nephrotic syndrome. 
1) Arterial underfilling – proteinuria results in hypoalbuminemia with 
decrease oncotic pressure causing fluid loss from intravascular 
space reduce plasma and blood volume with resultant activation of 
homeostatic responses involving sympathetic nervous system, and 
the rennin-angiotension-aldosterone axis. 
2) Sodium retention directly induced by an intrinisic defect in the 
kidney. 
The importance in recognizing these two different factors is that 
clinically nephrotic patient are very often massively oedematous.  Diuretic 
therapy will usually relieve the oedema but it could lead to worsening 
hypovalaemia if underfilling is an important mechanism in specific patient. 
A reduction in the plasma serum albumin concentration should 
increase the gradient between the capillary and interstitial oncotic pressure 
thus favouring aflux of fluid from the vascular to interstitial space.  The 
reality is that in patient with nephrotic syndrome the loss of albumin is 
gradual and there tend to be similar gradual loss in the interstitial oncotic 
pressure secondary to increase lymphatic flow.  Thus the trans capillary 
oncotic pressure gradient may stabilize, and thus limit fluid flux into the 
interstitiium (23). 
 Overall it’s likely that both mechanisms contribute in a variable degree 
to the oedema in each patient (24). 
1.1.7 Histopathological Classification: 
1.1.7.1     Minimal change NS 8- MCNS 
By definition only slight abnormalities are apparent on renal histology 
in MCNS, by light microscopy.   
Examination of glumeruli in MCNS by electron microscopy reveals 
widening and effacement of the visceral epithelial cell foot processes, with 
consequent loss of slit processes – so called foot process fusion (25). 
1.1.7.2   Focal global glomerulosclerosis: (FGGS) 
1.1.7.3   Focal segmental glomerulosclerosis: (FSGS) 
1.1.7.4   Mesangial proliferative glomerulonephritis (MPN)  
1.1.7.5   Membranoproliferative glomerulonephritis (MPGN)  
1.1.7.6    Membranous glomerulonephritis (MGN)   
 
1.1.8     Clinical Manifestation of Nephrotic Syndrome: 
The disease may occur during the 1st year of life, but it usually started 
between the age of 2 and 7 years, with male : female ratio 2 : 1(8). 
It’s characterized by a sudden onset, oedema being the major 
presenting symptom, and becomes clinically detectable when fluid retention 
exceeds 3 to 5% body weight.  Oedema is gravity dependent, localize to the 
lower extremities in the upright position and to the dorsal part of the body in 
the reclining position, this oedema is soft and pitting, Anasarca may develop 
with scites and pleural and pericardial effusions.  Oedema of scrotum and 
penis or labia may be seen.    Abdominal pain is occasionally cause by a 
complication such as, peritonitis, thrombosis or rarely pancreatitis.  
Cardiovascular shock can occur as a result of the sudden fall of plasma 
albumin, with abdominal pain and symptomatic peripheral circulatory failure 
with cold extremities and hypotension.    Blood pressure is usually normal 
but sometimes elevated. 
The nephrotic syndrome is occasionally discovered during routine 
urine analysis.   
A typical clinical presentation substantially lower the likelihood that 
the child has idiopathic minimal change nephrotic syndrome(27), these 
include: hypertension, haematuria, prednisone resistance and age: (post 
puberty and less than 1 year). 
 
1.1.9     Diagnosis of Nephrotic Syndrome: 
1.1.9.1   Urine analysis for proteinuria:   
2 Urine dipstick:  It primary detect albumin and is highly specific but 
not very sensitive for detection of proteinura(28).   
3 Sulfosalicylic acid test:  (SSA)   
In contrast to urine dipstick, SSA detect all protein in the urine. 
? Quantitative measurement of proteinuria: 
? The ISKDC definition of nephrotic syndrome in children as 
proteinuria greater than 40 mg/m2/hr in an overnight specimen of 
urine or greater than 1 g/m2/24 hrs. 
? And alternate method is protein : creatinine or albumin : creatinine 
ratio – the upper limit of urine  albumin to creatinine ratio in 
overnight urine sample in children is 2 mg/mmol (0.02 mg/mg) (29) 
and value less than 10 mg/mmol  (0.09 mg/mg) is taken as indicating 
remission nephrotic syndrome and alternatively overnight urine 
protein: creatinine ratio of more than 200 mg/mmol (1-8 mg/mg) 
taken as indicating nephrotic syndrome(30). 
1.1.10 Biochemical analysis: 
1.1.10.1       Serum albumin level usually less than 2.5 g/dl 
1.1.10.2 Serum cholesterol and triglyceride level are elevated. 
1.1.10.3 Total calcium level is diminished due to reduction in albumin 
bound fractin. 
1.1.10.4 The erythrocyte sedimentation rate (ESR) is elevated (greater than 
25 mm/hr) in almost all patient with nephrotic syndrome and a 
direct relation between the degree of proteinuria and the ESR was 
approximately 10 time the daily rate of protein excretion(31-32). 
1.1.11  Renal biopsy: 
A renal biopsy usually not performed until after therapeutic trial of 
glucocorticoids has to be unsuccessful, exception to this general rule may be 
made in the following situation(33): 
1.1.11.1 A child age below one year or older than 10 year at onset of 
nephrotic syndrome. 
1.1.11.2  Co-existence of significant haematuria, hypertension and 
azotema at the onset of nephrotic syndrome (a typical 
nephrosis).  
1.1.11.3 Any child in whom the level of serum complement (or C3) are 
depressed. 
1.1.11.4 Patient with frequent relapses or who are steroid resistant. 
 
 
 
1.1.12 Complication of Nephrotic Syndrome: 
1.1.12 .1   Infection: 
Nephrotic children are prone to serious bacterial sepsis.  Indeed the 
major improvement in the mortality of the condition came not with 
corticosteroids, but with the introduction of antibiotics particularly 
penicillin(34).  The classical infection is a primary peritonitis with 
streptococcus pneumoniae, sometimes associated with septicemia(35).  
Hemophilus influenzae may cause a similar illness, and infections with gram 
negative organisms are common.  The stretched skin and oedematous 
subcutaneous tissue predispose patients to cellulites. 
1.1.12.2    Thromboembolic phenomena: 
Patient with the nephrotic syndrome have an increase incidence (10-
40%) of arterial and venous thromboemboli, particularly deep peripheral vein 
and renal vein thrombosis.   
Enhancement of platelet aggregation and decrease level of 
antithrombin secondary to urinary losses and the presence of high molecular 
weight fibrinogen moieties in the circulation have been found.  An addition 
explanation to increase hypercoagulibility is that immune mediated injury in 
the glomerulus results in increased procoagulent activity that is sufficient to 
have a systemic effect.   
The net effect of the hyper coagulable state is further enhanced in 
patients due to immobility, coincidental infection and hemoconcentration(36-
37).  
1.1.12.3   Hypovoleamia: 
Symptomatic hypovolemia can occur in nephrotic patients often as a 
result of diuresis in those with serum albumin less than 1.5 g/dl. Occasional 
untreated children show sign of volume depletion thought to be due to sever 
hypoalbuminemia causing fluid movement into interstitium. 
1.1.12.4   Renal failure 
Renal function is usually within normal limits at presentation.  A 
reduction of GFR secondary to hypvolemia is common. 
Bohman et al(38) showed a close relationship between the degree of 
foot process fusion and both GFR and filtration fraction.  
Acute renal failure may be secondary bilateral renal vein thrombosis 
or interstitial nephritis.   
The main difference between responders and non responders is the 
tendency of latter to develop End Stage Renal Failure (ESRF).   
  Progression of ESRF has been reported to be more rapid in patients 
ofAfrican or Hispanic descent when compared with Caucasians            Ingulli 
and Tegani found that among 57 African – American and Hispanic children.  
50% of them had reached ESRF in 3 years and 95% reached this stage after 6 
years (39). 
In addition among children with idiopathic NS, the proportion of 
those with steroid resistant FSGS tends to be greater in African – American 
and Haspanic children.  
   
1.1.13     Management of Nephrotic Syndrome: 
1.1.13.1    Symptomatic management: 
? Oedema: 
It’s the commonest manifestation is managed by both salt and water 
restriction.  Loope diuretics may be added but vigorous diuresis especially in 
children should be avoided since it may lead to decline in effective plasma 
volume because of the difficult transfer of extracellular fluid into the 
intravascular compartment.  This may lead to reduction in GFR and 
hypotension. 
Iv salt-free human albumin 20% (20 mg/kg) has a relative short half 
life and is usually excreted in 24-48 hours and therefore its effect in raising 
ancotic pressure will be transient.  Its use may be called upon in dire 
situations when the oedema became overwhelming or endangering to life like 
in tight ascites pleural effusion that embarrasses breathing, refractory 
anasarca or postural hypotension.    
? Thromboemboli: 
Nephrotic patients with severe hypoalbuminemia are at risk of 
thromboembolic complication: preventive measures include mobilization 
avoidance of hypovolemia, early treatment of sepsis or volume depletion.  
Prophylactic warfarin therapy is controversial  and it may be given to high 
risk patients with plasma albumin concentration below 20 g/L or fibrinogen 
level over 6 g/L or antithrombin III level below 70% of normal (40).  
? Bacterial infection: 
Prophylaxis against streptococcus pneumoniae with oral penicillin is 
often used in patient with massive oedema. 
In cases of peritonitis antibiotic against both streptococcus and gram 
negative organism are started after peritoneal fluid sampling(41). 
? Hypertension 
Children with NS usually normotensive.  If the blood pressure 
exceeds the normal limit, for age and sex – then short term treatment in 
nifedipine (0.25 – 1 mg/kg) per day in two doses, and/or atenolol (0.5 – 1 
mg/kg/day once) can be used in cases of permanent hypertension and ACE 
inhibitor is preferred. 
 
1.1.13.2     Steroid therapy: 
Steroid therapy considered the cornerstone treatment of MC NS.  
Some paediatricians prefer to wait for some time before initiating this therapy 
if the disease is mild since some 5% of such children may remit 
spontaneously.  The rationale behind such therapeutic policy is to avoid side 
effects of un-necessary steroid. 
The international study of kidney disease in children (35) protocol 
consists of prinisolone 60 mg/m2/day given in divided doses and usually 
proteinuria disappeared in the second week in many children.  Thereafter, 
pridnisolone is continued at the same dose for 30 days and then patient is 
switched to alternate day therapy at dose of 40 mg/m2 (single dose/day) for 
two months.  Thereafter the alternate day dose is decreased by 10-15 mg/m2 
every two weeks.  The net effect of total duration of therapy for the newly 
diagnosed patient is 4-5 month.  
While the protocol for treatment of relapsers was based on a 
recommendation of (ISKDC): which consist of pridnisolone 60 mg/m2 per 
day continue for three days after the urine has become protein free, 
thereafter, alternate day pridnisolone 40 mg/m2 (single dose) given for four 
weeks(5). 
Frequent relapses and those who relapse when the steroid dose is 
either discontinued or reduced, ie steroid dependent dose a clinical problem 
and one of two regimens may be chosen: either prednisolone in a dose of 60 
mg/ m2/day to be continued for 3 days after a partial remission followed by 
40 mg/ m2 surface area an alternate days for 4 weeks or following 3 days of 
partial remission, alternate day therapy is tapered to reach the patient’s 
steroid threshold for a period of 12-18 months. The 1st of two regimens is 
characterized by more relapses since the duration of the therapy is shorter(42) 
partial remission is defined as a protein free state sustained for a minimum 
period of three days while steroid threshold is the dose at which a relapse has 
occurred. 
1.1.13.3 Alkylating agent: 
 Patient who are frequent relapses and those who are steroid dependent 
should be treated with different therapeutic modalities that avoid steroid 
since prolonged steroid therapy has various complications eg: growth 
retardation, obesity, catatact and so on.  In this aspect alkalating agent like 
cyclophosphamide and chlorambucil can be given to induce long testing 
remission while minimizing steroid side effect(43).   
 Other therapies include: levamisole and cyclosporine. 
1.1.13.4 Steroid resistance:  A subset of children with MCNS fail to 
respond to corticosteroid treatment. These children tend to develop the 
disease at a younger age a progress to End Stage renal failure but fortunately 
no recurrence is experienced following transplantation.  Genetic factors and 
down regulation of glucocorticoid receptors are two mechanism put forward 
to explain why these children don’t respond to steroid.  The genetic factor 
constitutes an autosomal recessive trait (44,45). 
 It would be wise to withdraw steroid in these patient to avoid side 
effects.  Cyclophosphamide alone does not have a benefit over that of 
corticosteroids.  Various aggressive protocols have been tried in this category 
of patients these include pulse methyprednisolone (MP) followed by 
cyclophosphamide or chlorabucil for a period of 2-3 months intermittent 
pulse MP for approximately 18 months or combination of cyclosporine with 
prednisolone.  
 The common strategy is that children with resistant disease may be 
offered aregimen of cyclosporine plus prednisolone if GFR is normal while 
cyclophosphamide or chlorabucil may be tried in those with impaired GFR. 
 
1.1.14      Lipid of Physiological Significant: 
1.1.14.1 Definition: 
 Lipids are hetrogenous group of organic compounds that are actually 
or potentially esters of fattyacids.  They have the common properties of being 
relatively insoluble in water and soluble in non polar compounds(46). 
 
1.1.15 Biochemical importance: 
 Lipids are important dietary constituents because they are source of 
high energy value, fat soluble vitamin and essential fatty acid.  They play 
many roles in the body eg adipose tissue serve as storage from of energy and 
as thermal insulator.  Non polar lipid act as electrical insulators allowing 
rapid propagation of depolarization wave along myelinated nerves, finally 
lipoprotein enter the structure of cell membrane and mitochorcha(47). 
 
 
1.1.16 Classification of Lipid: 
1.1.16.1 Simple lipids: 
 Are esters of fatty acids with various alcohols devided into: 
- Fats (acylglycerol): in 
liquid state in room 
temperature is known 
as oil while that on 
solid state is known as 
fats. 
- Wax  
1.1.16.2 Complex lipids: 
 Are esters of fatty acid containing groups in addition to an alcohol and 
fatty acid?. 
? Phopholipid:  main lipid constituent of membrane. 
? Glycolipid: important in nerve tissue 
? Others  (48)    
1.1.17 Precursor and derived lipids: 
 These include fatty acid, glycerol steroid and fatty aldehydes. 
1.1.17.1   neutral lipids: 
Are those which carry on charges and include neutral fat 
(acylglycerols), cholesterol and cholesteryl ester(49) plasma lipid in humans are 
triglyceride (TG) 45%, total phospholipids 35%  total cholesterol (TC) 15% 
and free fatty acid < 5%. 
 
? Cholesterol: 
 In an alcohol that occur in the circulation in two forms.  The free 
cholesterol account for about 30% and it is the form that exchange readily 
between different lipoproteins and cell membrane.  Then other form 
accounting for remainder 70% (storage form). 
? It’s essential structural component of plalsma lipoprotein and cell 
membrane. And it’s precursor of all other steroid in the body eg sex 
hormones(50). 
? About have of body cholesterol areises by synthesis (700 mg/day) in 
the liver (10%), the intestine (10%) and other organs. 
Its mainly a product of animal origin eg meet or in it’s counter part in 
plants named phytosterol(51).  
? Triglyceride: 
 Are quantitively the most significant lipids. They are important as a 
major constituent of lipoproteins and as storage form in adipose tissue.  
Triglyceride is the major portion (98-99%) of animal lipids the reminder being 
cholesterol and others. 
? Fatty acid: 
 Non essential fatty acid synthesized in the body from acetyl CoA. 
 
? Lipoprotein: 
 Are hetrogenous group of lipid protein complexes synthesized mainly 
in the intestine and liver and serve a wide variety of functions in the blood: 
 Transporting lipids from tissue to tissues and participating in lipid 
metabolism. 
 Four major groups of lipoproteins have been identified in normal 
fasting human: very low density lipoprotein (VLDL), low density lipoprotein 
(LDL), intermediate density lipoprotein (IDL), high dentisty lipoprotein 
(HDL) and a fifth type name chylomicorn in the post abortive period(52). 
1- VLDL: (pre-B-lipoprotein); 
 Mostly derived from the liver for export of TG to extrahepatic tissue – 
in plasma it is converted to IDL and LDL. 
2- LDL (B-lipoprotien): 
 Represents the final storage of VLDL is the major transporter of 
cholesterol in the plasma (53). 
3- HDL: (-Lipoprotein) transport the cholesterol from tissue to liver. 
 Triglyceride is the predominant lipid in the chylomicron and 
(VLDL).  Phospholipids is predominant lipid in HDL and cholesterol 
is predominant lipid in (LDL) the purified protein component of a 
lipoprotein particle is called a polipoprotein, each type of lipoprotein 
has a characteristics a polipoprotein compositon eg. APOA, is 
prominent in HDL(54). 
 
1.1.18 Clinical application: 
 Abnormalities of lipoprotein metabolism occur either at the sites of 
production or utilization of lipoproteins causing various hypo (decrease/or 
hyper lipidemias (increase). 
1.1.18.1 Screening of lipids in children: 
 Interest in the study of plasma lipids has been at it’s high tint for the 
last one to two decades because of close association between hyperlipidemia 
and development of astherosclerosis in children.  There was a controversy 
whether cholesterol should be searched for by universal or by selective 
screening or by no screening at all(55,56). 
 In recent years cholesterol has been the third and nationally 
recommended health screening test in United State population and is highly 
recommended by the national heart, lung and blood institute for both adult 
and children(57). 
 Lipid level show differences in different populations and are shown to 
be affected by age, sex, height, life style, infection and genetics(58). 
 Several screening studies have been reported in children of different age 
and from popultion in study by Knuiman and his group in 1983, plasma 
cholesterol level in children age 8-9 years from different countries were 
compared.  The result showed variation in cholesterol levels, the highest level 
was in children from Finland while the lowest was in children from 
Ghana(59). 
 Mohsen A.F. Elhazimi in the year (2001), studied the prevalence of 
lipid abnormalities in Saudi children age 1-15 year and found that the 
prevalence of lipid abnormality varied in the different age group where the 
higher mean (TG) was in 3-4 year old and the lowest in those aged 8-11 years 
(these changes in lipid may result from sexual maturation and related 
hormonal levels.  Cholesterol level were found to be lower than those 
reported in Finland, new Zealand and Italy and similar to Philippine 
population and higher than the population in some African countries(60).  
 As part of an epidemiological study on cardiovascular risk factor 
among children and adolescents in Navara: lipids and lipoproteins were 
analyzed in 5829 children age 4-17 years of both sex.   
 Results showed prevalence of hypercholesterolemia of about 21.7%, 
the lipid risk of LDL/HDL is very high (15-70%) and male adolescents turn 
out to be the group with the highest risk(61). 
 Hyperlipidemia and atherosclerosis group in Canada analyzed the 
relationship between APOE phenotype and plasma lipid levels in 45 
population samples from 17 different countries (1992) result indicate a 
consistent relationship between plasma (TG) level and apoE phenotype 
among different population and that (TG) concentrations were significantly 
higher in apoE2 than ApoE3 and that (HDL) is significantly lower in APOE4 
than APOE3
(62). 
 
Whom to be screened? 
 Measurement of total cholesterol or lipid profile should be performed 
only under certain defined circumstances.  The American Academy of 
Pediatrics (AAP).  The American Heart Association (AHA) and National 
Cholesterol Program (NCP) don’t recommend routine total cholesterol 
screening in children. 
 Indications of cholesterol testing together with the recommended tests 
are as follows(63,64): 
? In children as general (above the age of two years). 
? Parent with TG of 240 mg/dl or more ? measure  
? Family history of premature Coronary Heart Disease (CHD) ? 
measure fasting lipid profile. 
? Family history of dyslipidemia (abnormal lipid profile) measure 
fasting lipid profile. 
? Paediatric medical condition that predisposes pts to CHD of 
dyslipidemia ? measure fasting lipid profile. 
 
1.1.19 Significance of Blood Cholesterol Level in Childhood 
and Adolescent: 
 The mean blood total cholesterol level of American children and 
adolescents is roughly 160 mg/dl the mean low lipoprotein (LDL) cholesterol 
level is about 100 mg/dl from 1 to 19 years of age, the 75th percentile for total 
cholesterol is roughly 170 mg/dl, the 95th percentile for total cholesterol is 
roughly 200 mg/dl and for LDL cholesterol about 130 mg/dl. 
 
The National Cholesterol Education Program  (NCEP) determined the 
different plasma levels in children in mg/as shown in table below(85). 
Table: 
Children < 20 
years 
Desirable  
level 
Border line 
level 
Elevated  
level 
TC < 170 170 - 199 > 200 
LDL.C < 110 110 – 129 > 130 
HDL.C > 45 35 – 45 Low when < 35 
TG < 125  > 125 
 
 High blood cholesterol level clearly plays a role in the development of 
CHD in adult.  This has been established by many laboratory, clinical, 
pathologic and epidemiologic studies.  A variety of studies also have 
demonstrated that the atherosclerotic process begins in childhood and is 
affected by high blood cholesterol levels.  The evidence can be summarized 
as follows: 
? Compared to their counter parts in the many other countries, USA 
children and adolescents have higher blood cholesterol levels and 
higher in takes of saturated fatty acids and cholesterol and adults have 
higher rate of CHD. 
? Autopsy studies demonstrate that early coronary atherosclerosis often 
begin in childhood or adolescence. 
? High serum total cholesterol, LDL cholesterol and very low density 
lipoprotein ((VLDL) cholesterol levels and low high density 
lipoprotein (HDL) cholesterol levels are correlated with the extent of 
early atherosclerotic lesions in adolescents and young adults. 
? High blood cholesterol aggregates in families as a result of both 
shared environments and genetic factors. 
? Children and adolescents with high cholesterol level are more likely 
than general population to have high levels in adults(65). 
Persistent nephrotic syndrome is frequently accompanied by severe 
hyperlipidemia.  The plasma lipoprotein profile is characterized by elevated 
level of total lipids (cholesterol, triglycerides), and often enormous increase in 
cholesterol in low density lipoprotein (LDL), and very low density 
lipoprotein (VLDL) cholesterol fraction, whereas the concentration of high 
density lipoprotein (HDL) cholesterol is normal or even decreased.  
Persistent “nephrotic dyslipidemia” constitutes a risk factor for early 
atherosclerosis (66,67). 
Therapy resistant nephrotic syndrome almost in variably lead to 
progressive renal in sufficiency which is histologically characterized by 
progressive glumerulosclerosis and tubulointestinal fibrosis. 
This development is now regarded by many investigators as an active 
process, driven by pathobiological mechanisms analogous to atherosclerosis 
(68,69). 
Hyperlipoproteinemia therefore also seems to be a risk factor for the 
progression of renal insufficiency.  This concept has received support from 
studies in nephrotic animal showing that progressive renal disease could be 
accelerated by diet induced  hyperlipidemia and vice versa, i.e the 
development of glomerulosclerosis could be retarded by antihyperlipidemic 
drugs (70,71). 
Cardiovascular complications due to atherosclerosis are the leading 
cause of death in the adult dialysis and transplant population(72).  Since most 
paediatric patients with chronic renal disease now survive their childhood 
and adolescent years, it has become impossible for the pediatric nephrologists 
to ignore the importance of risk factor for cardiovascular disease, as they 
seem to be major limiting factors for long term patient survival. 
Hyper lipidemia is probably the most common cardiovascular risk 
factor in children with renal disease.  It’s typically found in patients wit 
idiopathic nephrotic syndrome(73). 
What is “nephrotic hyper lipidemia”? 
Almost patients with nephrotic syndrome or nephrotic range 
proteinuria (> 1 g/m2 per day) have elevated total cholesterol levels, although 
unexplained exceptions do occur as already reported.  In studies in the early 
1960s (74) the plasma cholesterol concentration showed an inverse hyperbolic 
correlation with plasma albumin, accompanied by stem rise in triglycerides in 
patients with severe hypoalbuminema.   
In plasma, lipids are bound to lipoproteins, and the disturbance in lipid 
metabolism in the nephrotic syndrome result in increased levels of 
lipoproteins (hyper lipoproteinemia)  and remodeling of the composition of 
lipoproteins  (dyslipoproteinemia).  The term nephrotic hyperlipidemia 
therefore is not a good description of the complicated change that take place 
inplasma, but its use is wide spread and therefore it’s used in this view. 
If lipoprotein classes are separated by ultra centrifugation, the increase 
concentrations of total plasma lipids can be shown to result mainly from 
elevations in LDL and VLDL, the main carriers of cholesterol and 
triglycerides, respectively in plasma.  LDL particles are usually elevated in 
patients with minimal glumerular change, but normal or low in persistent 
nephrotic syndrome (75).  
The lipoprotein profile in these chronic patients therefore comprises 
elevated levels VLDL cholesterol and LDL cholesterol and frequent 
decreased HDL-cholesterol. 
Children with proteinuria often have highly elevated plasma levels of 
atherogenic and thrombogenic LP (a) (76) although related to presence of 
proteinura, the pathogenesis of this abnormality is not completely 
understood. 
The clinical significance of high LP (a) levels in proteinuric patient has 
not been proven, but there is a high level of suspicion that LP (a) could be 
involve in cardiovascular disease and thromboembolic events (77). 
 
Why does nephrotic hyperlipidemia occur? 
Most authors agree that the increased hepatic synthesis of lipoproteins 
is essential for the development of hyperlipidemia in nephrotic syndrome, 
and that the degree roughly correlates with the disease severity.  The signal 
for the increased lipoprotein production might be a low plasma oncotic 
pressure, since dextran infusions and albumin infusions were shown to lower 
plasma lipids.  More recent work has shown that the loss of albumin or other 
liporegulatory substances in the urine is more likely to confer the signal for 
increasing lipoprotein production.   
In mild to moderate idiopathic nephrotic syndrome increased hepatic 
synthesis of VLDL leads to accumulation of LDL particles (provided that 
plasma lipolysis is intact, which also produces some cholesterol transfer from 
VLDL to HDL), thus increasing mainly cholesterol (LDL and HDL) levels in 
plasma. 
Patients with sever nephrotic syndrome also have hyper 
triglyceridemia, this is best explained by decrease lipolysis of triglyceride – 
rich particle (VLDL) in plasma. 
A low activity of plasma lipoprotein lipase (LPL) has been shown to 
correlate with elevated triglyceride (78,79). 
Thus, a combination of increased hepatic synthesis and decreased 
removal of lipoproteins from plasma is thought to be present in “severe” 
forms of idiopathic nephrotic syndrome.  In these patients we sometimes find 
enormously increase lipoproteins, with cholesterol and triglycerides 
frequently exceeding 400-500 mg/dl, or even 1000 mg/dl, as in children with 
congenital nephrotic syndrome (80). 
 
Is Nephrotic hyperlipidemia associated with clinical risk? 
In view of the usually slow development of cardiovascular disease, this 
question has been studied exclusively in adult.  In a large prospective study 
(159 patients, sex and age matched controls) with a mean follow up of 5 
years, no increase risk of cardiovascular disease was noted (81). 
More recently a large case – control study including 142 patients and 
142 matched controls demonstrated an increase risk of coronary heart disease 
in adult patients with nephrotic syndrome (defined as proteinura ? 3.5 g/day) 
(82). 
In nephrotic children there is only some anecdotal evidence of 
myocardial infarction or document atherosclerosis.  Although being 
remarkable in view of long history of the development of atherosclerosis 
complication, it cannot be ruled out these cases are due to the chance 
occurrence of primary (genetic) form of hyperlipidemia or coagulation 
abnormalities in association with nephrotic syndrome. 
 
 
1.1.20 Management of nephrotic hyperlipidemia: 
The rational for treatment of nephrotic hyperlipidemia is that: in view 
of cited evidence for an increase risk of atherosclerosis, it seems straight 
forward to treat hyper lipidemia in nephrotic subjects for preventive reasons.  
There is also evidence that hyperlipidemia contributes to the progression of 
renal insufficiency in nephrotic patients.  the hypothesis that increased 
plasma lipids are nephrotic was first proposed by Moorhead et al 1982 (83). 
 
 
1.1.20.1 Available lipid lowering drugs: 
Although dietary fat restriction is usually recommended in hyper 
lipidemic states, modest fat restriction is hardly effective in nephrotic 
syndrome (84). 
Dietary supplementation with fish oil has some lipid lowering effects.  
However, in an animal model of protein uria and renal insufficiency, it leads 
to functional and histological renal deterioration (85). 
The five major classes of lipid lowering drugs are bile-acid sequestrants, 
fibric acid derivatives, nicotinic acid (derivatives), probucol and HMG-CoA 
reductase inhibitors (Statins). 
In general, they are widely used in adult patients with primary or 
secondary forms of hyper lipidemia, but experience in hyper lipidemia 
children has mainly been confined to patients with FH. 
1.1.20.2    Which lipid-lowering drugs can be considered for treatment of 
hyper lipidemia in children with nephrotic syndrome? 
In children with minimal change disease, hyper lipidemia rapidly 
normalize after disappearance of proteinuria, although exceptions have been 
recorded (86) in prepubertal children with persistent nephrotic syndrome 
cholestyramine, sitosterol or fibrale can be used with careful monitoring for 
the side effect.  Nephrotic children generally tolerate bezafibrate or 
gemfibrozil well. 
Nicotic acid should be avoided because of potential side effects.  
Probucol has disadvantage of prolonging QT interval in some patients (87). 
Limited controlled experience with station has been documented in 
children with FH.  In animal experiments station caused stunted growth and 
severe myopathy.  Therefore it’s our current practice to avoid statin in 
children with nephrotic syndrome. 
At present the only lipid-lowering drugs recommended by the National 
Cholesterol Education Program for use in children are bile acid sequestrants. 
? The decision for treatment:  Yes or No? 
In view of the available evidence it seems logical to treat 
hyperlipidemia in patient with unremitting nephrotic syndrome for 
preventive reasons.  However, the decision for treatment with lipid-lowering 
drugs at present is based on beliefs and unproven benefits.   
The absence of clearly define therapeutic end point and concerns about 
possible side effects are clear limitations for any therapeutic decisions. 
Principally, however, treatment decisions are hard to make because of 
the general lack of published studies in children (88). 
 Role of plasma albumin deficiency in experimental nephrotic 
hyperlipidemia and hyper cholesterolemia was studied by Rosemann et al in 
San Francisco in 1956. 
 The previous studies suggested that the external loss of some plasma 
substance via the urine of the rat, following injection of antirat kidney serum 
(AKS was the cause of development of hyperlipidemia of experimental 
nephrotic syndrome.  Since albumin is one of plasma substance known to be 
excreted in great quantity in this syndrome, studies is pursued to determined 
if the external loss of this substance was responsible for the development of 
this hyperlipidemia. 
 Plasma obtained from 12 normal rats (group 2/ also are included for 
purpose of comparison.  The control rat the infused with normal saline for 24 
hrs following injection of AKS exhibited a fall of total protein and albumin 
and a rise of total lipid and cholesterol in their plasma similar to that observe 
in untreated nephrotic rats. 
 In contrast the infusion of albumin for 24 hours following injection of 
AKS prevent the usual of plasma total proteins and albumin in this group of 
rats.  And their rise of plasma total lipids and cholesterol was of considerably 
lesser magnitude in comparison to control animals and entirely prevented in 
a number of these rats(93). 
 Increased abnormal lipoprotein patterns were found in serum of 
nephrotic syndrome, observation seen by J. S. Chopra et al in Manchester (94). 
 33 patient with nephrotic syndrome some of whom were in 
spontaneous or steroid induced remission.  17 of the patients had abnormal 
lipoprotein patterns, in 82% of which increase concentrations of both (B) and 
(pre B) lipoprotein were found.  And because of association between 
hyperlipidemia and ischemic heart disease it’s advisable to examine 
lipoprotein pattern of all subjects with nephrotic syndrome and to treat any 
significant abnormality. 
 
1.1.21 Studies Done on Lipid Profile: 
 Litle is known about lipid abnormalities in nephrotic children. 
 Plasma totalcholesterol, LDL-cholesterol levels and triglyceride were 
high in children with nephrotic syndrome.  This was proved by A- merouani 
et al in their study. 
 Twenty five children with NS at remission with or without active 
prednisolone treatment, were compared with those an age matched 
population (2003); they found that plasma total and LDL cholesterol levels 
were about the 95th percentile for age and sex in 12 of the 25 patients (48%) 
with 7 of them having a polipoprotein B and triglyceride concentrations 
above the 95th percentile.  Moreover frequently relapsing children were more 
likely to have abnormal lipid profile during the remission (89). 
 Gasten Zilleruelo et al studied severity and duration of hyperlipidemia 
in 59 nephrotic children during relapse and remission.  Serum total 
cholesterol and triglyceride values were > 95th percentile for age and sex in all 
patient with minimal change nephrotic syndrome in relapse and in patients 
with non-MCNS and persistent proteinuria.  Most of these patients also had a 
significant elevation of low and very low density lipoproteins.  A significant 
number of children with MCNS during prolong remission had elevated 
serum of total cholesterol (46%), triglyceride (42%), LDL (29%) and VLDL 
(40%).  Persistence and severity of lipid change correlated well with duration 
of disease and frequency of relapses.  Significantly decreased HDL and 
HDL/LDL were found inpatients with non MCNS and persistent 
proteinuria.  Our results suggest that nephrotic children may have prolonged 
periods of hyperlipidemia even after clinical remission.  In addition, some of 
these children with significant decrease HDL/LDL may be at increased risk 
of developing premature atherosclerosis (90). 
 Studies done on adults patient showed correlation between the degree 
of proteinuria and serum lipid levels. 
Khanna et al studied hyperlipidemia in adults with nephrotic syndrome 
(in 1985):  Thirty patients with proteinuria were studied: 20 of whom had 
proteinuria of nephrotic range (10 had proteinuria of nephrotic range (group 
I) and 10 had proteinuria of non nephrotic range (Group II). 
 A 24 hrs urine protein was estimated by Esbach’s method, also serum 
cholesterol, plasma triglyceride and lipoprotein electrophoresis were 
performed. 
 The result was serum lipid values were significant elevated in Group I 
when compared with group II (91).  
 In a study done in (ZECH) total cholesterol, HDL, LDL and TH were 
determined before any treatment in 15 patient with nephrotic syndrome.  
Eight patients with proteinuria higher than 10 g/24 hrs and 7 with 
proteinuria between 5-10 g/24 hrs. 
 They found that disorder of lipid metabolism is more serious in patient 
with more severe nephrotic syndrome than in nephrotic with milder 
proteinuria (92).  
 Correlation between hyperlipidemia and renal impairment was studied 
by Joseph Stelzmam Strasse who mentioned that dyslipidemia may enhance 
progression of renal impairment in patients with residual renal function(99). 
 
 
?   Justification and Objectives 
 
• Justification: 
? Prolonged hyperlipidemia has been shown to: 
o Accelerate atherosclerosis  
o Lead to progression of renal insufficiency 
? Early identification of lipid abnormalities may aids in early 
management and prevention of complication. 
? Sudanese children has different dietary, constitutional and genetic 
background hence we undertook a study to determine the spectrum 
of lipid abnormalities in our children with nephrotic syndrome. 
? No similar study was done in Sudan. 
 
 
 
  
 
 
• Objectives: 
1- To determine lipid profiles in Sudanese children with nephrotic 
syndrome. 
2- To determine the possible risk factors for development of 
hyperlipidemia such as: 
a. Duration of illness        b.  Degree of hypoalbuminemia 
  c.  Hypertension       d.  Degree of renal impairment       
 
 
 
 
 
 
 
 
  
 
Chapter Two 
2- Patients and Methods 
 
2.1 Study Design: 
This is a cross sectional hospital based study. 
1.2 Study Area: 
The study was conducted in Dr. Salma Dialysis and Kidney Transplant 
Centre, and main Khartoum State Paediatric Teaching Hospitals including 
Soba, Omdurman and Gaafar Ibn Auf Children’s Emergency Hospital. 
1.3 Study Population: 
The study included children who had been diagnosed as having 
nephrotic syndrome for at least 6 months or more. 
1.4 Study Period: 
The study was conducted during a period of 6 month, from March 
2006 to August 2006. 
 
  
1.5 Inclusion Criteria: 
All children diagnosed as nephrotic syndrome (for 6 month or more) 
and less than 18 years who came for follow up in above mentioned clinics 
were enrolled in the study. 
1.6 Exclusion criteria: 
o Newly diagnose nephrotic syndrome. 
o Presence of acute illness 
o Refusal of children and/or their parent to participate in the 
study. 
2.7 Sample size: 
 Calculated according to advice of statistician using the equation: 
N  =  Z2XPXQ 
         D2 
Where: 
Z = Statistical certainty = 1-96 
P = Prevalence (2-5) 
Q = Probability of failure = (1 – P) 
d = Desired margin of error (0.05) 
Sample size = 30 
 The minimal sample size is 30 patients and the study sample included 
60 children who  presented with nephrotic syndrome. 
2.8 Ethical approval: 
Written approval of the study was obtained from the above mentioned 
hospital administrators. 
Verbal consent was obtained from children, their parent and/or their 
guardians. 
2.9 Methods: 
2.9.1 Definitions: 
? The case definition of nephrotic syndrome: 
o Children who present with heavy proteinuria  (urine protein > 1 
g/m2/24 hrs),  hypoalbuminemia (serum albumin < 2.5 g/dl),  
and generalized oedema. 
? Remission:  Urine albumin nil or trace (proteinuria < 4  mg/m2/hr) for 
3 consecutive days. 
? Relapse:  Urine albumin 3+ or 4+ (or protein > 40 mg/m2/hr) for  3 
consecutive days, having been in remission previously. 
? Frequent relapses: Two or more relapses in six month of initial 
response or more than three relapses in any twelve months. 
? Steroid dependence: two consecutive relapses while on alternate day 
steroid or within 14 days of its discontinuation. 
? Steroid resistance: absence of remission despite therapy with 4 weeks of 
daily prednisolone in a dose of 2 mg/kg/day (100). 
? Body mass index: is classified into four categories: 
o Underweight ?  < 5 kg  
o Normal ? 5 - > 85 kg 
o Borderline ? 85 - < 95  
o Overweight ? > 95th  
? Blood pressure: is classified into: 
o Normal ? > 90th centile 
o Borderline ? 90th – 95th centile 
o Severe hypertension > 95th centile. 
2.9.2 Questionnaire: 
Information on age, sex, locality, duration of illness, and number of 
relapses were collected in a questionnaire sheet. 
The last section contains clinical examination data and investigation 
results. 
2.9.3 Clinical examination: 
Every child was subjected to a clinical examination with emphasis on 
weight using stand on scale, height using unstretchable tape, blood pressure 
using mercury sphygmomanometer with appropriate cuff sizes. The presence 
or absence of signs of hyperlipidemia, periorbital buffness, ascites and lower 
limbs oedema were recorded.  Examination were done by author. 
2.9.4 Investigations: 
2.9.4.1 Sample collection and storage: 
All patients were requested to fast for at least 8 hours.  After 
sterilization using 70% alcohol, 2 ml of blood were withdrawn with        a 
disposable syringes into a heparinized tube to be centrifuged within 3 hours 
to extract plasma and then collected in a plane container for lipid profile test.  
Tubes (containers) were coded with serial numbers, stored in the 
refrigenerator at 2-8 oC and analyzed within 7 days. 
2.9.4.2 Urine for protein, RBCs, Cast and RBCS. 
2.9.4.3 Estimation of 24 hours urine protein. 
2.9.4.4 Blood sample for urea, creatinine, Na+, and K+ 
 
3.10         Statistical Methods: 
Data was entered in computer using the Statistical Package of Social 
Science (SPSS) system. 
Frequencies were obtained for all variables and chi square tests were 
computed for selected variables.  The level of significance was taken as P = 
0.05 and fissure exact test was used in frequencies of less than 5. 
3.11 Input of the author: 
The task of questionnaire completion, performing the clinical 
examination and collection of blood sample were conducted by the author. 
3.12 Other participant: 
Laboratory technician in biochemistry department, Khartoum 
University participated a lot in this study together with colleges in pediatrics. 
3.13 Funds and Grants: 
The research was done with self resources with no external funds. 
 
 
 
 
 
 
 
 
Chapter Three 
3- Results 
 
3.1 Demographic Characteristics of Study Group: 
A total number of 60 children who fulfilled the criteria of nephrotic 
syndrome were enrolled in this study during the period from March 2006 
until August 2006 in Dr. Salma Centre for Renal Dialysis and Transplant, 
Khartoum Teaching Hospital, Omdurman Teaching Hospital and Soba 
Teaching Hospital in Khartoum State. 
3.1.1 Age characteristics of the study group: 
 The age of studied group ranged between 2 years and 5 years, with a 
peak age of 5 years (43.3%) with a mean 8.4 + 4.06 years.  
 Children < 5 years of age constituted 26 patients (43.3%) those between 
6-10 years were 12 (20%) and those above 10 years were found to be 22 
(36.7%).  (Figure 1) 
3.1.2 Gender characteristics of the study group: 
In this study there was male predominance,  38 patients (63.3%)  of 
the study group, and 22 patients (36.7%) were females, male to female ratio 
of 2.1 : 1. (Figure 2) 
  
Figure 1: Age groups of study group (n = 60)
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Figure (2): Gender distribution of study group (n = 60) 
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3.1.3 Origin: 
The majority (66.6%) of children in this study were from    Central 
states (Khartoum, Gazeira) 20 patients from each state.  Twelve patients 
(20%) were from the north, 5 patients (8.3%) were from the south, 2 patient 
(3.3%) were from the west and only one patient (1.7%) was from the east. 
(Figure 3) 
3.2 History of lipidogenic diet: 
The majority of children in study group were not on lipidogenic diet, 
only 5 patients (8.3%) of study group use to take egg yolk and 2 patient 
(3.3%) of study group use to take animal fat. (Table 1) 
 
3.3 Drug History: 
Out of 60 patients enrolled in this study,  59 patient (98.3%) were on 
steroid therapy, 34 patient (56.7%) were on diuretics, 15 patient (25%) were 
on antihypertensive drugs, 13 patients (21.6%) on  cyclophosphamide and 
cyclosporine and others 5 (8.3%). (Table 2) 
 
 
 
 
  
Figure (3): Origin of study group (n = 60) 
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Table 1: History of Lipidogenic diet  
n = 60 
 
 Egg Yolk Animal Fat 
 No % No % 
Yes 5 8.3 2 3.3 
No 55 91.7 58 96.7 
Total 60 100 60 100 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Drug history 
n = 60 
 
  
Steroid 
 
Diuretic 
 
Antihypertensive 
  
Cyclophosphamide 
cyclosporine  
 
Others 
 
 No % No % No % No % No % 
Yes 59 98.3 34 56.7 15 25 13 21.6 5 8.3 
No 2 1.7 26 43.3 45 75 47 78.4 55 91.7 
Total 60 100 60 100 60 100 60 100 60 100 
 
 
 
 
 
 
 
 
 
 
3.4 History of related diseases: 
• All children of study group had no history of  hypothyroidism or 
diabetes. 
• No patient of study group had a family history of coronary heart 
disease (CHD). 
• Family history of obesity was found in two patient (3.3%), of this 
study non of them was obese.   
3.5 Duration of the Illness: 
In 20 patients (33%) the duration of nephrotic syndrome was 6/12 – 1 
year.  A similar number had a duration of > 1-3 years and > 3 years i.e. 20 
patients in each group. (Figure 4) 
3.6 Clinical Examination: 
3.6.1 Anthropometric measures: 
3.6.1.1 Weight centiles of the study group: 
 Out of sixty patients enrolled in this study22 patients  (36.7%) were 
between  3rd - < 50th centile, 23 patient (38.3%) were between  50th  - < 75th 
centile, 12 patient (20%)  between  75th  - < 90th centile, 2 patients (3.3%)  
between 90th – > 95th centile and 1 patient  (1.6%) at > 95th centile. (Figure 5) 
   
  
Figure (4): Duration of illness in study group (n = 60) 
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Figure (5): Weight centile of study group
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Figure (6): Height in the study group
 
 
 
 
 
 
 
 
 
 
 
3.6.1.2 Height centiles of study group: 
In this study 21 patients (35%) were at < 3rd centile, 24 (40%) were 
between 3rd and 50th centile,  5 patient (8.3%) were at 75th centile  ,7 patients 
(11.6%) were at 90 thcentiles and only 3 patients (5.1%) were at > 95th centile. 
(Figure 6) 
3.6.2 Body mass index (BMI): 
In this study 26 patients (43.3%) were found to be under-weight (BMI 
< 5) where as 23 patient (38.3%) were of normal weight (BMI 5th  - < 85th ) 
and 8 patient (13.3%) were borderline (MBI 85th  - < 95th ) and only 3 patient 
(5%) were found to be obese (BMI > 95th) (Figure 7) 
3.6.3 Blood pressure centile of study group: 
Out of 60 children with nephrotic syndrome in this study 45 patient 
(75%) had normal blood pressure (< 90th centile), 9 patient (15%) had 
borderline blood pressure (90th - < 95th centile) and the remaining 6 patients 
(10%) had severe hypertension.  (Table 3)  
3.6.4 Signs of hyperlipidemia 
No child in study group had  any sign of hyperlipidemia. 
 
  
 
Table 3: Blood pressure in study group 
n = 60 
 
Blood pressure 
(centile) 
Frequency Percentage 
Normal BP  45 75 
Bborderline hypertension  9 15 
Severe hypertension  6 10 
Total 60 100 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure (7):  Body mass index of the study group
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3.7 Investigations: 
In this study 60 children with nephrotic syndrome were included and 
the following laboratorial investigations were done. 
3.7.1 Serum albumin level: 
Fourty two patients (70%) had serum albumin > 1.5 -< 3.5 while 18 
patient (30.0%) had serum albumin < 1.5 mg/dl.  (severe hypoalbuminemia) 
. (Figure 8) 
3.7.2 Renal function of the study group: 
Renal function was assessed by the mean of  calculated GFR, and it 
showed 36 patient (60%) of the study group had a normal renal function  i.e. 
GFR > 50 ml/min/1.73 m2,  11 patients (18.3%) had mild renal impairment 
(GFR 30-50 ml/min/1.73 m2,  ) and 13 patients (21.7%) had moderate renal 
impairment (GFR 30 - > 10).  None had severe renal impairment(GFR <10 
ml/min/1.7m2).  (Figure 9) 
 
 
 
 
 
 
 
Figure (8): Serum albumin of study group
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Figure (9): Renal function in the study group 
 
 
 
 
 
 
 
 
 
 
3.7.3   Lipid profile in a study group: 
In this study serum cholesterol was high in 40 patients (66.7%) and 
borderline in 12 patient (20%).  The remaining 8 patients (13.3%), had 
normal   serum cholesterol . 
LDL cholesterol was elevated in 38 patient (63.3%) and borderline in 
11 patient (18.3%).  The remaining 11 patient (18.3%) had normal LDL. 
Triglyceride level was high in 38  patients  (63.3%) ,and was normal in 22 
patients (36.7%).  
HDL: was low in 16 patient (26.7%), borderline in 21 patients (35%)  
high in 3 patients (5%) and normal in 20 patients (33.3%). (Table 4)  
3.8 Classification of Study Group According to Respond to 
Steroid Therapy:   
Sixty children with nephrotic syndrome were enrolled in this study.  Of 
those, 48 patients (80%) were steroid sensitive, while 12 patients (20%) were 
steroid resistant. (Figure 10).  Among those who were steroid sensitive, 25 
patients (41.7%) were infrequent relapser or no relapse while 23 patients 
(38.3%) were frequent relapses or steroid dependent. (Figure 11) 
 
 
Table 4: Lipid profile in study group: 
 
 Cholesterol LDL TG HDL 
 No % No % No % No % 
Normal 8 13.3 11 18.3 22 36.7 20 33.3 
Border 
line 
12 20 11 18.3 0 0 21 35 
Elevated  40 66.7 38 63.4 38 63.3 3 5 
Low 0 0 0 0 0 0 16 26.7 
Total 60 100 60 100 60 100 60 100 
P.V. 000   0.017  0.96  0.64  
 
 
 
 
 
 
 
 
 
 
 
  
Figure (10):  Classification of study group according to response to steroid therapy
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3.9 Correlation Between Hyperlipidemia and Risk Factors: 
3.9.1 Duration of illness: 
Out of 40 patients with elevated serum cholesterol, 18 patients (45%) 
had their nephrotic syndrome for more than 3 years duration,  11 (27%)  had 
the disease duration of 1-3 years whereas the remaining 11 (27%) had the 
disease for 6 month – 1 year.  The difference was statistically significant. (P = 
0.01). 
Out of 38 patients ( 63.3%) with elevated LDL level ,16 patients 
(42.1%) had nephrotic syndrome for more than 3 years duration.  Nine 
patients (23.7%) had the disease duration of 1 - 3 years whereas the 
remaining 13 patients (34.2%) had the disease for 6 month – 1 year.  The 
difference was statistically significant. (P = 0.01) 
Out of 38 patients (63.3%) with elevated triglyceride level ,14  patients 
(36.8%)  had a nephrotic syndrome for more than 3 years duration. Eleven 
patie.ts (28.9%)  had the disease duratiol 1 - 3 year whereas the remaining 13 
patients (34.2%) had the disease for 6 month – 1year.  The difference was 
statistically insignificant. (P = 0.09) 
 (Figure 12)   
 
 
3.9.2 Correlation between hyperlipidemia  and serum albumin: 
• Out of 40 children with elevated cholesterol 22 (55%) had serum 
albumin > 1.5 – < 3.5 whereas 18 patients   18 (45%) children had serum 
albumin level < 1.5 mg/dl. The difference was statistically  significant. (P = 
0.002) 
Out of 38 children (63.3%) with elevated LDL level 23 (60.5%) had 
serum albumin > 1.5 – < 3.5 whereas 15 patients   (39.5%) children had 
serum albumin level < 1.5 mg/dl. The difference was statistically significant. 
(P = 0.04) 
Out of 38 children(63.3%) with elevated TG level 29 patients (76.3%) 
had serum albumin > 1.5 – < 3.5 whereas 9 patients   (23.7%) had serum 
albumin level < 1.5 mg/dl.  The difference was statistically insignificant. (P 
= 0.1).   (Figure 13) 
 
 
 
 
 
 
 
 
Figure (12): Correlation between hyperlipidemia and duration of 
nephrotic syndrome
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3.9.3            Correlation between hyper lipidemia and blood pressure: 
Out of 40 patient with elevated serum cholesterol,  26 patient (65%) had 
normal blood pressure, 9 patient (22.5%) had borderline blood pressure, the 
remaining 5 patients (12.5%) had severe hypertension.  The difference is 
statistically significant (P = 0.03). 
Out of 38 patient with elevated LDL,  22 patient (57.8%) had normal 
blood pressure, whereas 10 patient (26.4%) had borderline blood pressure, 
the remaining 6 patients (15.8%) had severe hypertension.  The difference 
statistically significant (P = 0.01). 
Out of 38 patient with elevated TG,  29 patient (76.3%) had normal 
blood pressure, whereas 6 patient (15.8%) had borderline blood pressure, 
the remaining 3 patients (7.9%) had severe hypertension.  The difference is 
statistically insignificant (P = 0.96). (Table 5) 
 
 
 
 
 
 
Table 5: Correlation between hyperlipidaemia and blood pressure 
centile  
n = 60 
 
 Cholesterol LDL TG 
 No % No % No % 
  Normal BP  26 65 22 57.8 29 76.3 
 Borderline hypertension  9 22.5 10 26.4 6 15.8 
  severe hypertension 5 12.5 6 15.8 3 7.9 
Total 40 100 38 100 38 100 
P.V. 0.03  0.01  0.96  
 
 
 
 
 
 
 
 
 
3.9.4 Correlation between hyperlipidemia and renal function:  
Out of 40 patients with elevated serum cholesterol, 23 patients 
(57.5%) had impaired renal function whereas 17 patients (42.5%) had normal 
renal function.  Of those with impaired renal function 13 patients (56.5%) 
had moderately renal impairment whereas 10 (43.4%) patients had mild renal 
function impairment.  The difference is statistically significant. (P = 0.003) 
Out of 38 patients with elevated LDL,  21 patients (55.3%) had 
impaired renal function whereas  17 patients (44.7%) had normal renal 
function.  Of those with impaired renal function 11 patients (52.4%) had 
moderately renal impairment whereas 10 (47,6%) patients had mild renal 
function impairment.    The difference is statistically significant. (P = 0.033) 
Out of 38 patients with elevated TG, 13 patients (34.2%) had impaired 
renal function whereas  25 patients (65.8%) had normal renal function.  Of 
those with impaired renal function 5 patients (38.5%) had moderately renal 
impairment whereas 8 patients (61.5%) had mild renal function impairment.   
The difference is statistically insignificant. (P = 0.10) 
All 3 patients with elevated HDL had normal renal function test.  The 
different is statistically insignificant. (P = 0.80) (Table 6) 
3.9.5 Correlation between hyperlipidemia  and body mass index:  
In this study, out of the 40 patient with elevated serum cholesterol, 22 
patients (55%) were underweight, 11 patient (27.5%) has normal weight, 
whereas 7 patient (11.6%) were border line.  None of them was obese.  The 
different is statistically border line  (P = 0.06). 
Out of the 38 patient with elevated LDL, 18 patients (47.4%) were 
underweight, 13 patients (34.2%) has normal weight, whereas 7 patients 
(18.4%) were border line.  None of them was obese. The different is 
statistically insignificant. (P = 0.54) 
Out of the 38 patient with elevated TG, 17 patients (44.7%) were 
underweight, 15 patients (39.5%) has normal weight, whereas 6 patient 
(15.8%) were border line.  None of them were obese. The different is 
statistically insignificant. (P = 0.87).  (Table 7) 
 
 
 
 
 
Table 6: Correlation between hyperlipidaemia and renal function  
 
 Cholesterol LDL TG 
 No % No % No % 
Normal 17 42.5 17 44.7 25 65.8 
Mild 10 25 10 26.4 8 21.1 
Moderate 13 32.5 11 28.9 5 13.1 
Total 40 100 38 100 38 100 
P.V. .003   0.033  0.10  
 
 
 
 
 
 
 
 
 
 
 
Table 7: Correlation between hyperlipidaemia and body mass index 
 
 Cholesterol LDL TG 
 No % No % No % 
Underweight 22 55 18 47.4 17 44.7 
Normal 11 27.5 13 34.2 15 39.5 
Borderline 7 17.5 7 18.4 6 15.8 
Obese 0 0 0 0 0 0 
Total 40 100 38 100 38 100 
P.V. 0.06   0.5  0.87  
 
 
 
 
 
 
 
 
 
3.10 Correlation Between Hyperlipidemia and Age Groups: 
Out of 40 patients with elevated serum cholesterol, 18 patients (45%) 
were < 5 years old, whereas 7 patient (17.5%) between 6-10 years old, and 
the remaining 15 patients (37.5%) were > 10 years old.  The different 
statistically insignificant (P = 0.30).      
Out of 38 patients with elevated LDL, 18 patients (47.1%) were < 5 
years old, whereas 7 patients (13.4%) between 6-10 years old, and the 
remaining 13 patients (34.2%) were > 10 years old.   The different was 
statistically insignificant. (P = 0.8) 
Out of 38 patients with elevated TG, 20 patients (52.7%) were < 5 
years old, whereas 9 patients (23.7%) between 6-10 years old, and the 
remaining 9 patients (23.7%) were > 10 years old.    The different was 
statistically significant. (P = 0.05).   (Table 8) 
 
 
 
 
 
 
 
Table (8):  Correlation between hyperlipidemia and age group 
 
  
 
 
 
 
 
 
 
3.11 Correlation Between Hyperlipidemia and Gender: 
Age group Cholesterol LDL TG 
 No % No % No % 
< 5 18 45 18 47.4 20 52.7 
6 – 10 7 17.5 7 18.4 9 23.7 
> 10 15 37.5 13 34.2 9 23.7 
Total 40 100.0 38 100.0 38 100.0 
P.V.  0.3  0.8  0.05 
This study showed that, out of 40 patients with elevated cholesterol, 24 
patients (60%) were male, whereas 16 patients (40%) were female.   The 
different was statistically insignificant. (P = 0.69). 
This study showed that, out of 38 patients with elevated LDL, 24 
patient (63.2%) were male, whereas 14 patients (36.8%) were females.   The 
different was statistically insignificant.  (P = 0.8). 
This study showed that, out of 38 patients with elevated TG, 26 
patients (68.4%) were male, whereas 12 patients (31.6%) were female.    The 
different was statistically insignificant. (P = 0.2).  (Table 9) 
 
 
 
 
 
 
 
 
 
 
Table 9: Correlation between hyperlipidaemia and gender 
  Cholesterol LDL TG 
 No % No % No % 
Male 24 60 24 63.2 26 68.4 
Female 16 40 14 36.8 12 31.6 
Total 40 100 38 100 38 100 
P.V. 0.69   0.67  0.028  
 
 
 
 
 
 
 
 
 
3.12 Correlation Between Hyperlipidaemia and Response to 
Steroid Therapy: 
Out of 48 patients with steroid sensitive nephrotic syndrome (SSNS) 
included in this study, 28 patients (58.3%) had elevated cholesterol, whereas 
all those 12 patients (100%) with steroid resistant had elevated cholesterol.  
The different is statistically significant. (P = 0.002). 
Twenty seven patients (56.2%) SSNS cases had elevated LDL, 
whereas 11 patients (91.6%) of those steroid resistant had elevated LDL.  The 
different is statistically borderline (P = 0.06). 
Twenty nine patients (60.4%) of those who were SSNS had elevated 
TG whereas 9 patients (75%) with steroid resistant had elevated TG.   The 
different is statistically insignificant. (P = 0.34).  (Table 10) 
 
 
 
 
 
 
 
Table 10: Correlation between hyperlipidaemia and response to steroid 
therapy 
 Cholesterol LDL TG 
 No % No % No % 
SSNS  28 58.3 27 56.2 29 60.4 
SRNS 12 100 11 91.6 9 75 
P.V. .002   0.06  0.34  
 
 
 
 
 
 
 
 
 
 
 
3.13 Correlation between Hyperlipidaemia and Pattern of 
Relapse: 
Out of  28 patient with steroid sensitive nephrotic syndrome with high 
cholesterol 20 patient (71.4%), were either frequent relapser or steroid 
dependent whereas  8 patient (28.6%) were infrequent relapser. The different 
is statistically significant. (P = 0.001). 
Out of 26 patient with steroid sensitive nephrotic syndrome with high 
LDL 20 patient (71.4%), were either frequent relapser or steroid dependent 
whereas 6 patient (23.1%) were infrequent relapser.   The different is 
statistically highly significant. (P = 0.000). 
Out of 28 patients with steroid sensitive nephrotic syndrome with high 
TG 16 patient (57.1%), were either frequent relapser or steroid dependent 
whereas 12 patient (42.9%) were infrequent relapser.  The different is 
statistically insignificant. (P = 0.13).   (Table 11). 
 
 
 
 
 
 
Table 11: Correlation between hyperlipidaemia and pattern of relapse 
 
 Cholesterol LDL TG 
 No % No % No % 
Infrequent relapsers 8 28.6 6 23.1 12 42.9 
Frequent relapser or 
steroid dependent 
20 71.4 20 76.9 16 57.1 
Total 28 100 26 100 28 100 
P.V. .001   0.000  0.31  
 
 
 
 
 
 
 
 
 
3.14 Correlation Between Hyperlipidaemia and stage of the 
disease (i.e. remission or relapse): 
When this study was conducted 49 patients (81.7%) were in remission 
while 11 patients (18.3%) were in relapse (Table 12).  29 patients of those on 
remission had elevated cholesterol (59.2%) while all those on relapse had 
elevated cholesterol (100%).  The difference is statistically significant. (P = 
0.03). 
Serum LDL was found to be elevated in 27 patients (55.1%) in  those 
in remission in all those on relapse (100%).  The different is statistically 
significant. (P = 0.02).   
Serum TG was found to be elevated in 31 patients (63.2%) in 
remission, and in 7 patients (63.6%) of those on relapse.  The different is 
statistically insignificant. (P = 0.9).   (Table 13) 
 
 
 
 
 
 
 
 
 
Table 12:  Patient state at the time of study conduction 
n = 60 
  Frequency Percentage 
(%) 
Remission 49 81.7 
Relapse 11 18.3 
Total 60 100 
 
 
 
 
 
 
 
 
 
 
Table 13: Correlation between hyperlipidaemia and stage of disease 
(i.e. remission or relapse) 
 
 Cholesterol LDL TG 
 No % No % No % 
Remission 29 59.2 27 55.1 31 63.2 
On relapse 11 100 11 100 7 63.6 
P.V. . 03   0.02  0.98  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
4- Discussion 
 Only few studies have been published about the 
hyperlipidemia in nephrotic children(88). 
4.1 Demographic Characteristics of the Study Group: 
4.1.1 Age characteristics of study group: 
A total of 60 patients with nephrotic syndrome were studied 
during the period March 2006 to August 2006.  The age of children 
in this study ranged between two years to 15 years with a peak of 2-
5 years and mean of 8.4 + 4.06 years.  The mean was similar to that 
in other studies, which was conducted in Canada (87). 
4.1.2 Sex characteristics of study group: 
The study showed obvious male predominance, where males 
constituted 38 (63.3%) of the study group, and females were 22 
(36.7%), that gave a male to female ratio ( M : F) 2.1 : 1.  This male 
predominance was documented in other study done in United 
States of America with the same ratio. However, another study 
done in Monitored, Canada showed females predominance with 
female : male 1 : 0.9 (88).   
4.1.3 Origin characteristics of study group: 
The majority of children in the study were from Khartoum 
and Central State.  This finding may reflect lack of adequate 
medical facilities and specialist doctors in the rural area to diagnose 
or refer patients with nephrotic syndrome. 
4.2 Nutritional History: 
Most children in the study group were found not to be on 
lipidogenic diet.   
In this study 5 children (8.3%) use to take egg yolk and only 2 
children (3.3%) of study group use to take animal fat, this may 
reflect the boor socioeconomic state  of most of the study  group . 
4.3  History of related disease: 
 In this study, it had been found that almost all children had no 
history of hypothyroidism and non had diabetes or family history of 
CHD, this was similar to study conducted in Miami (88) in which the 
above mentioned three histories where excluded. 
In this study it had been found that there is thirteen patient 
with moderate renal impairment in comparison to study conducted 
in Canada in which all patient were of normal renal function (87). 
4.4 Prevalence of hyperlipidemia in study group: 
This study documented that serum cholesterol, LDL levels 
were above 95th percentile for age and sex in all patients with 
nephrotic syndrome in relapse, and in all those with steroid 
resistance. For those in remission the prevalence of serum 
cholesterol, LDL and triglyceride were  59.2%,  55.1%   and  63.2% 
respectively.                                                                                        
     These finding are similar to that reported by 
Gastonzilleruelo et al(88), 1984 who showed that serum cholesterol 
and LDL were elevated in all patient in relapse state and in all 
those with steroid resistance. For those in remission, our results are 
higher than what has been reported in that study(88) regarding 
cholesterol level (59.2% versus 49), LDL (55.1% versus 29% ), TG 
(63.2% versus 42%). This difference could be explained by the fact 
that Merouani’s study included only those in remission whereas our 
study included patients in remission as well as those on relapse. The 
latter group expected to have high prevalence of hyperlipidemia . 
Regarding steroid sensitive group, the prevalence of 
hyperlipidemia was found to be higher in frequent relapsers or 
steroid dependent patients than in those with infrequent relpasers. 
This is similar to what has been reported by Merouani's study, and 
this could  be explained by the fact that frequent relapses and 
steroid dependent are brone to have more persistent proteinuria and 
hypoalbuminemia which are risk factor of developing 
hyperlipidemia .    
HDL cholesterol values were low in our study fact that is 
similar to that documented by Khanna et al(87).  
 
 
 
4.5 Correlation Between Hyperlipidemia and Risk Factors: 
4.5.1 Duration of illness:  
 This study documented that both cholesterol and LDL 
hyperlipidemia were positively correlated with duration of 
nephrotic syndrome.  Similar results were reported by Gaston 
Zilleruelo, et al. Another   study done by H. Merouani showed no 
correlation(87,88). The difference could be explained by the fact that  
Merouany’s study included steroid  resistant cases which are 
expected  to have more prolonged illness and with more persistence 
of  hyper lipidemia.  Or this could be related to the small number of 
patients in that study.   
4.5.2 Correlation Between Hyperlipidemia and Serum albumin:   
It had been found in this study that serum albumin had            a 
significant inverse correlation with serum cholesterol, this is in agreement 
with study done by Ray H. Rosenman who documented that the 
hyperlipidemia observed in the experimental nephrotic syndrome is initiated 
and maintained by the renal loss of albumin. The results also similar to that 
of study done in USA and India (88,89,97). 
 
4.5.3 Correlation Between Hyperlipidemia and Hypertension:    
In this study it was found that, there was significant positive 
correlation between high blood pressure and hyperlipidemia.  No similar 
studies showed such observations.  
 
 4.5.4  Correlation Between Hyperlipidemia and Renal impairment:  
 In this study it had been found that there is thirteen patient with 
moderate renal impairment in comparison to study conducted in Canada in 
which all patient were of normal renal function (87). 
This study documented that renal impairment correlated with 
hyperlipdiemia, this is in agreement  with that found  in study done in 
germany by Joseph Stelzmann Strasse who reported that days lipidemia may 
enhance progression of renal disease in patient with residual renal 
function(98).     
 
 
 
4.5.5      Correlation Between Hyperlipidemia and Obesity: 
Also obesity had no effect on hyperlipdiemia in this study, obese 
children were found.   
There is association between childhood obesity and cardiovascular 
disease.  In Muscatine study obese children had low HDL, other studies 
provided conflicting result and don’t prove that relation between obesity and 
CHD(7). 
 
 
 
 
 
 
 
 
?   Conclusions 
? Nephrotic syndrome was found to be one of causes of 
hyperlipidemia. 
? Prevalence of hypercholesterolemia was observed to be highest in 
relation to other lipid profile variables and showed higher percentage 
in male gender. 
? Hyperlipidemia of total cholesterol and LDL have positive 
correlation with renal impairment. 
? Risk factors positively correlated with lipid profile are duration of 
nephrotic syndrome, serum albumin and blood pressure. 
? Serum cholesterol and LDL were high in all patient (in study group) 
in relapse and in patient with steroid resistant. 
? Prevalence of hyperlipidemia is rather higher in frequent relapser 
and steroid dependent in compare to infrequent relapser. 
? Significant number of children with nephrotic syndrome during 
remission had elevated serum concentration of cholesterol, LDL and 
triglyceride. 
 
?    Recommendations 
 
? Nephrotic syndrome should be recognized and manage appropriately to 
avoid unnecessary complication. 
? Despite the disappearance of proteinuria, hyperlipidemia profiles were 
present in more than half of our nephrotic children at remission.  We 
therefore, recommend regular lipid monitoring during the follow up of 
nephrotic patients especially those with frequent relapses. 
? Assessment of renal function, and blood pressure should be measured, and 
follow up, in all children with nephrotic syndrome. 
? Children with significantly decrease HDL may be at increased risk of 
developing premature atherosclerosis. 
? Our results re-enforce the need for careful characterization of the lipid 
profiles in nephrotic patients, as this will help in the decision of treat in this 
component of nephrotic syndrome. 
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HYPER LIPIDEMIA IN CHILDREN WITH NEPHROTICSYNDROME IN 
KHARTOUM STATE 
Questionnaire 
 Serial No: ……………………………...……..  Date: ………………………….                               
Age Group:         
1. 0-2 Years ( ).      2. 3-6 Years (  ).        
3. 7-10 Years ( ).      4. 11-15 Years ( ).                                                                                 
Duration of illness: ………………… Number of relapses ……………..………                                  
 
A\ Personal Data:                            
1. Name: …………………………………………………………..…………….   
2. Sex:…………………………..….…   3. Age: ……………..……….…..……   
4. Present residence: ……………………………… 5. Tribe: ……………...…                                   
6. Original home:  1\ South ( )    2\ North (  )    3\ Center ( )                      
4\ East  ( )   5\ West  (  ).                                                                      
7. Address ……………….… 8. Telephone Number …….…………………….                                  
 
B\ Nutritional H: 
1\   ………………………...    1.Yes ( )  2. No ( ).   
2\ ..........................................     1. Yes( )  2. No ( ).                                     
 
C\ Druge H:   
1. Steroid (    )    2.  Diuretic (    )     3.  Antihypertensive (    )      
4.  Other (specify)………………………………..…………...…………………. 
D\ Clinical signs:     
General  :     
1. B.P ............................................ a. Normal (  )    b. High (  ).       
2. H.T…………….… Centile …..…… 3. W.T ……………….. Centile ………    
4. B- M. I …………………………….  5. S.A …………...…………………….                                  
E\ Signs of hyper  Lipdemia:   
1.……………………2……………………………….3……………….………                                    
 
F\ Investigations:     
1\ Urine  general:   1. Alb…..…..2.Pus cells….... 3. RBCs ……. 4.Cast …….           
2\ 24 hr  urine protein (Esbach,s test) …………. a. Normal(   ) b. High(   ).     3\ S. 
Urea   ……………………………………….    a. Normal(    ) b. High(   ).       
4\ S. creatinine ……………………………............ a. Normal (   )  b. High (   ).      
5\  S. Na………………..…………… 6\ S. k ………………….…………..……    
7\ Serum albumin …………………..   a- < 1.5 ( )    b-1.5-3.5 ( )      
8\ Serum cholesterol …………  Normal ( ) High (  ).                    
9\ S.TG ……………………...   Normal ( ) High (  ).  
10\ LDL ……………………..  Normal ( ) High (  ).   
11\ HDL …………………….  Normal ( ) High (  ). 
12\ VDL  ……………………  Normal ( ) High (  ). 
 
Diagnosis                                                                                                                                    
A\   
1- Steroid sensitive ( ):  
• Infrequent relapse (  ). 
• a- frequent replase    ( ).  
        b- Steroid dependent ( ).             
2- Steroid resistance (  ).   
                                                                                                                    
 B\   
1-Remission ( ).      
2-Relapse      ( ).                                                                                                                   
  
    
    
  
 
 
